DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial.
DNA vaccine immunogenicity has been limited by inefficient delivery. Needle-free delivery of DNA using a CO2-powered Biojector® device was compared to delivery by needle and syringe and evaluated for safety and immunogenicity.Forty adults, 18-50 years, were randomly assigned to intramuscular (IM) va...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2013-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3620125?pdf=render |
| _version_ | 1811327543168466944 |
|---|---|
| author | Barney S Graham Mary E Enama Martha C Nason Ingelise J Gordon Sheila A Peel Julie E Ledgerwood Sarah A Plummer John R Mascola Robert T Bailer Mario Roederer Richard A Koup Gary J Nabel VRC 008 Study Team |
| author_facet | Barney S Graham Mary E Enama Martha C Nason Ingelise J Gordon Sheila A Peel Julie E Ledgerwood Sarah A Plummer John R Mascola Robert T Bailer Mario Roederer Richard A Koup Gary J Nabel VRC 008 Study Team |
| author_sort | Barney S Graham |
| collection | DOAJ |
| description | DNA vaccine immunogenicity has been limited by inefficient delivery. Needle-free delivery of DNA using a CO2-powered Biojector® device was compared to delivery by needle and syringe and evaluated for safety and immunogenicity.Forty adults, 18-50 years, were randomly assigned to intramuscular (IM) vaccinations with DNA vaccine, VRC-HIVDNA016-00-VP, (weeks 0, 4, 8) by Biojector® 2000™ or needle and syringe (N/S) and boosted IM at week 24 with VRC-HIVADV014-00-VP (rAd5) with N/S at 10(10) or 10(11) particle units (PU). Equal numbers per assigned schedule had low (≤500) or high (>500) reciprocal titers of preexisting Ad5 neutralizing antibody.120 DNA and 39 rAd5 injections were given; 36 subjects completed follow-up research sample collections. IFN-γ ELISpot response rates were 17/19 (89%) for Biojector® and 13/17 (76%) for N/S delivery at Week 28 (4 weeks post rAd5 boost). The magnitude of ELISpot response was about 3-fold higher in Biojector® compared to N/S groups. Similar effects on response rates and magnitude were observed for CD8+, but not CD4+ T-cell responses by ICS. Env-specific antibody responses were about 10-fold higher in Biojector-primed subjects.DNA vaccination by Biojector® was well-tolerated and compared to needle injection, primed for greater IFN-γ ELISpot, CD8+ T-cell, and antibody responses after rAd5 boosting.ClinicalTrials.gov NCT00109629. |
| first_indexed | 2024-04-13T15:08:40Z |
| format | Article |
| id | doaj.art-3b852a8c202e41198b2ecf9667a79776 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-13T15:08:40Z |
| publishDate | 2013-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-3b852a8c202e41198b2ecf9667a797762022-12-22T02:42:04ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0184e5934010.1371/journal.pone.0059340DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial.Barney S GrahamMary E EnamaMartha C NasonIngelise J GordonSheila A PeelJulie E LedgerwoodSarah A PlummerJohn R MascolaRobert T BailerMario RoedererRichard A KoupGary J NabelVRC 008 Study TeamDNA vaccine immunogenicity has been limited by inefficient delivery. Needle-free delivery of DNA using a CO2-powered Biojector® device was compared to delivery by needle and syringe and evaluated for safety and immunogenicity.Forty adults, 18-50 years, were randomly assigned to intramuscular (IM) vaccinations with DNA vaccine, VRC-HIVDNA016-00-VP, (weeks 0, 4, 8) by Biojector® 2000™ or needle and syringe (N/S) and boosted IM at week 24 with VRC-HIVADV014-00-VP (rAd5) with N/S at 10(10) or 10(11) particle units (PU). Equal numbers per assigned schedule had low (≤500) or high (>500) reciprocal titers of preexisting Ad5 neutralizing antibody.120 DNA and 39 rAd5 injections were given; 36 subjects completed follow-up research sample collections. IFN-γ ELISpot response rates were 17/19 (89%) for Biojector® and 13/17 (76%) for N/S delivery at Week 28 (4 weeks post rAd5 boost). The magnitude of ELISpot response was about 3-fold higher in Biojector® compared to N/S groups. Similar effects on response rates and magnitude were observed for CD8+, but not CD4+ T-cell responses by ICS. Env-specific antibody responses were about 10-fold higher in Biojector-primed subjects.DNA vaccination by Biojector® was well-tolerated and compared to needle injection, primed for greater IFN-γ ELISpot, CD8+ T-cell, and antibody responses after rAd5 boosting.ClinicalTrials.gov NCT00109629.http://europepmc.org/articles/PMC3620125?pdf=render |
| spellingShingle | Barney S Graham Mary E Enama Martha C Nason Ingelise J Gordon Sheila A Peel Julie E Ledgerwood Sarah A Plummer John R Mascola Robert T Bailer Mario Roederer Richard A Koup Gary J Nabel VRC 008 Study Team DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial. PLoS ONE |
| title | DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial. |
| title_full | DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial. |
| title_fullStr | DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial. |
| title_full_unstemmed | DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial. |
| title_short | DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial. |
| title_sort | dna vaccine delivered by a needle free injection device improves potency of priming for antibody and cd8 t cell responses after rad5 boost in a randomized clinical trial |
| url | http://europepmc.org/articles/PMC3620125?pdf=render |
| work_keys_str_mv | AT barneysgraham dnavaccinedeliveredbyaneedlefreeinjectiondeviceimprovespotencyofprimingforantibodyandcd8tcellresponsesafterrad5boostinarandomizedclinicaltrial AT maryeenama dnavaccinedeliveredbyaneedlefreeinjectiondeviceimprovespotencyofprimingforantibodyandcd8tcellresponsesafterrad5boostinarandomizedclinicaltrial AT marthacnason dnavaccinedeliveredbyaneedlefreeinjectiondeviceimprovespotencyofprimingforantibodyandcd8tcellresponsesafterrad5boostinarandomizedclinicaltrial AT ingelisejgordon dnavaccinedeliveredbyaneedlefreeinjectiondeviceimprovespotencyofprimingforantibodyandcd8tcellresponsesafterrad5boostinarandomizedclinicaltrial AT sheilaapeel dnavaccinedeliveredbyaneedlefreeinjectiondeviceimprovespotencyofprimingforantibodyandcd8tcellresponsesafterrad5boostinarandomizedclinicaltrial AT julieeledgerwood dnavaccinedeliveredbyaneedlefreeinjectiondeviceimprovespotencyofprimingforantibodyandcd8tcellresponsesafterrad5boostinarandomizedclinicaltrial AT sarahaplummer dnavaccinedeliveredbyaneedlefreeinjectiondeviceimprovespotencyofprimingforantibodyandcd8tcellresponsesafterrad5boostinarandomizedclinicaltrial AT johnrmascola dnavaccinedeliveredbyaneedlefreeinjectiondeviceimprovespotencyofprimingforantibodyandcd8tcellresponsesafterrad5boostinarandomizedclinicaltrial AT roberttbailer dnavaccinedeliveredbyaneedlefreeinjectiondeviceimprovespotencyofprimingforantibodyandcd8tcellresponsesafterrad5boostinarandomizedclinicaltrial AT marioroederer dnavaccinedeliveredbyaneedlefreeinjectiondeviceimprovespotencyofprimingforantibodyandcd8tcellresponsesafterrad5boostinarandomizedclinicaltrial AT richardakoup dnavaccinedeliveredbyaneedlefreeinjectiondeviceimprovespotencyofprimingforantibodyandcd8tcellresponsesafterrad5boostinarandomizedclinicaltrial AT garyjnabel dnavaccinedeliveredbyaneedlefreeinjectiondeviceimprovespotencyofprimingforantibodyandcd8tcellresponsesafterrad5boostinarandomizedclinicaltrial AT vrc008studyteam dnavaccinedeliveredbyaneedlefreeinjectiondeviceimprovespotencyofprimingforantibodyandcd8tcellresponsesafterrad5boostinarandomizedclinicaltrial |